Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261351 | 0.87 | PARP1 (0.51) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL711986 | 0.86 | MAOA (0.43) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL711989 | 0.85 | MAPT (0.40) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL719982 | 0.85 | KMT2A (0.42) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL712224 | 0.85 | MAPT (0.41) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL12261358 | 0.84 | PARP1 (0.46) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL711990 | 0.83 | MAPT (0.39) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL714445 | 0.83 | MAPT (0.44) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL713014 | 0.83 | MAOA (0.41) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL10044133 | 0.83 | MAPT (0.43) | MAPTSMN1; SMN2KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470824-B2 | Substituted naphto[2,3-f]quinoxaline-7,12-diones and pharmaceutical utility thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-06-25 | — | — | US | disclosed |
| US-8470824-B2 | Substituted naphto[2,3-f]quinoxaline-7,12-diones and pharmaceutical utility thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-06-25 | — | — | US | disclosed |
| US-8445492-B2 | Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-05-21 | — | — | US | disclosed |
| US-8445492-B2 | Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-05-21 | — | — | US | disclosed |
| US-8222287-B2 | Substituted anthra[1,2-D]imidazolediones and pharmaceutical utility thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-07-17 | — | — | US | disclosed |
| US-8222287-B2 | Substituted anthra[1,2-D]imidazolediones and pharmaceutical utility thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-07-17 | — | — | US | disclosed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | disclosed |
| US-20110224218-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-09-15 | — | — | US | disclosed |
| US-20110224218-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-09-15 | — | — | US | disclosed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
| US-20100256155-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-10-07 | — | — | US | disclosed |
| US-20100256155-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-10-07 | — | — | US | disclosed |
| US-20100249143-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-09-30 | — | — | US | disclosed |
| US-20100249143-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-09-30 | — | — | US | disclosed |
| US-20090253707-A1 | HETEROANNELATED ANTHRAQUINONE DERIVATIVES AND THE SYNTHESIS METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
| US-20090253707-A1 | HETEROANNELATED ANTHRAQUINONE DERIVATIVES AND THE SYNTHESIS METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224218-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | TELO2, TERT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TNKS2 111/4885MAPT 4584/4885SMN1; SMN2 3777/4885 |
| US-20090253707-A1 | HETEROANNELATED ANTHRAQUINONE DERIVATIVES AND THE SYNTHESIS METHOD THEREOF | ANTXR2, RCC2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TNKS2 1682/4885MAPT 4881/4885SMN1; SMN2 4752/4885 |
| US-20100249143-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | TELO2, TERT, POT1 | TNKS2 241/4885MAPT 4799/4885SMN1; SMN2 2839/4885 |
| US-20100256155-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | TELO2, TERT, POT1 | TNKS2 241/4885MAPT 4799/4885SMN1; SMN2 2839/4885 |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | TERT, ACIN1, AK2 | TNKS2 55/4885MAPT 3490/4885SMN1; SMN2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.